Sucampo strikes supply deal

Sucampo Pharmaceuticals Inc., of Bethesda, a biopharmaceutical company, announced on Thursday that its subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement with its manufacturing and development partner, R-Tech Ueno Ltd., for clinical and commercial supplies of Amitiza. Amitiza treats chronic idiopathic constipation in adults and opioid-induced constipation in adults with chronic, non-cancer pain. Under the agreement, Sucampo receives a new, lower price for certain Amitiza components or finished product, except for the United States, Canada and Japan, where an agreement with Takeda Pharmaceutical Co. is in place until the end of 2020.

Leave a Reply

Your email address will not be published. Required fields are marked *